Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.

Autor:	Scalzulli, Emilia, Caocci, Giovanni, Efficace, Fabio, Rizzo, Lorenzo, Colafigli, Gioia, Di Prima, Alessio, Pepe, Sara, Fegatelli, Danilo Alunni, Carmosino, Ida, Diverio, Daniela, Latagliata, Roberto, La Nasa, Giorgio, Martelli, Maurizio, Foà, Robin, Breccia, Massimo
Předmět:	CHRONIC myeloid leukemia DASATINIB NILOTINIB PROTEIN-tyrosine kinases CHRONIC leukemia KINASE inhibitors THERAPEUTIC use of antineoplastic agents RESEARCH HETEROCYCLIC compounds PROTEIN kinase inhibitors RESEARCH methodology RETROSPECTIVE studies MEDICAL cooperation EVALUATION research TREATMENT effectiveness COMPARATIVE studies SURVIVAL analysis (Biometry) DRUG resistance in cancer cells
Zdroj:	Annals of Hematology; May2021, Vol. 100 Issue 5, p1213-1219, 7p
Abstrakt:	Tyrosine kinase inhibitors (TKIs), the backbone of treatment for chronic phase chronic myeloid leukemia patients (CP-CML), have changed the long-term outcome of the disease. Nonetheless, over 20% of patients fail front-line therapy due to intolerance or resistance. A head-to-head comparison of dasatinib and nilotinib as second-line treatment outside of sponsored clinical trials has not been reported. We retrospectively analyzed 131 CP-CML patients who, after front-line imatinib failure, switched to a second-line therapy with nilotinib (59, 45%) or dasatinib (72, 55%). Median duration of second-line treatment was 33 months (range 2-100). The reason for switching therapy was resistance in 83.2% and intolerance in 16.8% of patients. The overall survival of the entire cohort at 7 years was 78.9%, while it was 72% and 85.6% for patients treated with dasatinib and nilotinib, respectively (p=0.287). With regard to efficacy after 12 months of treatment, 108 patients were evaluable for molecular response: 47% achieved a major molecular response and 18.2% a deep molecular response with dasatinib, compared to 38% and 16.2% with nilotinib (p=ns). We observed 35% of grade 3-4 adverse events, more frequently in the dasatinib group (47%) compared to the nilotinib group (22%), without affecting molecular responses. Our study suggests that, in the real-life setting, dasatinib and nilotinib used as second-line treatment in CP-CML are equally effective, with high molecular response rates and an acceptable tolerability. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink